MMI raised $125 million in Series D financing to expand Symani commercialization, patient access, clinical research, and product development.
- Amount
- $125M
- Stage
- Series D
- Announced
- 9 October 2026
- Lead
- BioStar Capital
- Other investors
- S3 Ventures, Angelini Ventures
- Use of funds
- Global commercial expansion of the Symani Surgical System, improving patient access, and clinical research into new applications.
- Checked
- Amount and date matched across 2 press sources